Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avis Budget

61.95
+6.4611.64%
Post-market: 62.780.8320+1.34%19:43 EDT
Volume:2.11M
Turnover:126.99M
Market Cap:2.18B
PE:-1.21
High:63.18
Open:57.52
Low:55.69
Close:55.49
Loading ...

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

GlobeNewswire
·
24 Feb

Unpacking Q4 Earnings: Werner (NASDAQ:WERN) In The Context Of Other Ground Transportation Stocks

StockStory
·
24 Feb

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025

GlobeNewswire
·
24 Feb

Transport stocks take a hit on Wall Street on economic and tariff fears

Reuters
·
22 Feb

BUZZ-Transport stocks sink amid economy, tariff worries

Reuters
·
22 Feb

Winners And Losers Of Q4: Old Dominion Freight Line (NASDAQ:ODFL) Vs The Rest Of The Ground Transportation Stocks

StockStory
·
21 Feb

Hemogenyx Pharmaceuticals Secures Funding to Advance CAR-T Therapy Trials

TIPRANKS
·
20 Feb

Ground Transportation Stocks Q4 Teardown: Avis Budget Group (NASDAQ:CAR) Vs The Rest

StockStory
·
19 Feb

Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy

Stockheads
·
19 Feb

Stock Track | Avis Budget Soars 5.13% on Tuesday After Barclays Reaffirms Hold Rating

Stock Track
·
19 Feb

Carclo plc Sees Increased Stake by First Equity Limited

TIPRANKS
·
19 Feb

Anixa Biosciences: Advancing CAR-T Therapy and Cancer Vaccines with Strategic Trial Amendments and Robust Financial Position

TIPRANKS
·
19 Feb

Baird ‘encouraged’ by Allogene CAR-T therapy update

TIPRANKS
·
19 Feb

Avalon granted Notice of Allowance for CAR-T and CAR-NK cell technology in China

TIPRANKS
·
18 Feb

Anixa Biosciences announces approval of protocol amendment for CAR-T trial

TIPRANKS
·
18 Feb

Barclays Reaffirms Their Hold Rating on Avis Budget (CAR)

TIPRANKS
·
18 Feb